Roivant mosliciguat PHocus Phase 2 PH-ILD trial meets primary, secondary endpoints, Wainwright ups target

 

Roivant's mosliciguat PHocus Phase 2 PH-ILD trial meets primary and secondary endpoints as H.C. Wainwright raises target to $47

• PHocus Phase 2 trial in PH-ILD achieved large placebo-adjusted pulmonary vascular resistance reduction alongside primary, secondary endpoint success.
• Roivant initiated the Phase 3 PHrontier study of mosliciguat following positive efficacy findings from the PHocus Phase 2 trial.
• H.C. Wainwright raised its Roivant Sciences price target to $47 from $41 and reiterated a Buy rating.

https://finviz.com/stock?t=ROIV&p=d